XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Total revenue $ 82,422 $ 67,783
Biopharmaceutical revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 4,447 7,046
Contract manufacturing and testing    
Disaggregation of Revenue [Line Items]    
Total revenue 1,687 1,778
Biopharmaceutical and other revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 6,134 $ 8,824